PMID- 37033261
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230414
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Prognostic prediction and multidimensional dissections of a macrophages 
      M0-related gene signature in liver cancer.
PG  - 1153562
LID - 10.3389/fendo.2023.1153562 [doi]
LID - 1153562
AB  - BACKGROUND: Liver hepatocellular carcinoma (LIHC) is the seventh most commonly 
      diagnosed malignancy and the third leading cause of all cancer death worldwide. 
      The undifferentiated macrophages M0 can be induced into polarized M1 and M2 to 
      exert opposite effects in tumor microenvironment. However, the prognostic value 
      of macrophages M0 phenotype remains obscure in LIHC. METHODS: The transcriptome 
      data of LIHC was obtained from TCGA database and ICGC database. 365 LIHC samples 
      from TCGA database and 231 LIHC samples from ICGC database were finally included. 
      Macrophages M0-related genes (MRGs) were screened by Pearson correlation analysis 
      and univariate Cox regression analysis based on the infiltration level of 
      Macrophages M0. LASSO regression analysis was employed to construct a prognostic 
      signature based on MRGs, and risk scores were accordingly calculated. Then we 
      investigated the MRGs-based prognostic signature with respects to prognostic 
      value, clinical significance, strengthened pathways, immune infiltration, gene 
      mutation and drug sensitivity. Furthermore, the expression pattern of MRGs in the 
      tumor microenvironment were also detected in LIHC. RESULTS: A ten-MRG signature 
      was developed and clarified as independent prognostic predictors in LIHC. The 
      risk score-based nomogram showed favorable capability in survival prediction. 
      Several substance metabolism activities like fatty acid/amino acid metabolism 
      were strengthened in low-risk group. Low risk group was deciphered to harbor TTN 
      mutation-driven tumorigenesis, while TP53 mutation was dominant in high-risk 
      group. We also ascertained that the infiltration levels of immune cells and 
      expressions of immune checkpoints are significantly influenced by the risk score. 
      Besides, we implied that patients in low-risk group may be more sensitive to 
      several anti-cancer drugs. What's more important, single-cell analysis verified 
      the expression of MRGs in the tumor microenvironment of LIHC. CONCLUSION: 
      Multidimensional evaluations verified the clinical utility of the macrophages 
      M0-related gene signature to predict prognosis, assist risk decision and guide 
      treatment strategy for patients with LIHC.
CI  - Copyright (c) 2023 Xu and Wang.
FAU - Xu, Xiaoming
AU  - Xu X
AD  - Department of Gastroenterology, Jining First People's Hospital, Jining, China.
FAU - Wang, Jingzhi
AU  - Wang J
AD  - Department of Radiotherapy Oncology, The Affiliated Yancheng First Hospital of 
      Nanjing University Medical School, The First People's Hospital of Yancheng, 
      Yancheng, China.
LA  - eng
PT  - Journal Article
DEP - 20230324
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - Prognosis
MH  - *Liver Neoplasms/genetics
MH  - *Carcinoma, Hepatocellular/genetics
MH  - Nomograms
MH  - Tumor Microenvironment/genetics
PMC - PMC10080084
OTO - NOTNLM
OT  - immune infiltration
OT  - immunotherapy
OT  - liver cancer
OT  - macrophages M0
OT  - prognostic signature
OT  - single-cell analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/04/11 06:00
MHDA- 2023/04/11 06:41
PMCR- 2023/01/01
CRDT- 2023/04/10 03:51
PHST- 2023/01/29 00:00 [received]
PHST- 2023/03/14 00:00 [accepted]
PHST- 2023/04/11 06:41 [medline]
PHST- 2023/04/10 03:51 [entrez]
PHST- 2023/04/11 06:00 [pubmed]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1153562 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Mar 24;14:1153562. doi: 
      10.3389/fendo.2023.1153562. eCollection 2023.